Issue 1/2003
Content (9 Articles)
p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations
Elisa Sensi, Mariella Tancredi, Paolo Aretini, Giovanna Cipollini, A. Giuseppe Naccarato, Paolo Viacava, Generoso Bevilacqua, Maria A. Caligo
E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide
Sehwan Han, Kyeongmee Park, Byung-Noe Bae, Ki Hwan Kim, Hong-Joo Kim, Young-Duck Kim, Hong-Yong Kim
Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)
Ilka B. Fuchs, Solveig Landt, Helmut Bueler, Uwe Kuehl, Sarah Coupland, Anke Kleine-Tebbe, Werner Lichtenegger, Gerhard Schaller
Perioperative Screening for Metastatic Disease is not Indicated in Patients with Primary Breast Cancer and no Clinical Signs of Tumor Spread
Bernd Gerber, Eva Seitz, Heiner Müller, Annette Krause, Toralf Reimer, Günther Kundt, Klaus Friese
Predictive Factors for the Status of Non-sentinel Nodes in Breast Cancer Patients with Tumor Positive Sentinel Nodes
Vincent van Iterson, Marjut Leidenius, Leena Krogerus, Karl von Smitten
Keeping Data Continuous when Analyzing the Prognostic Impact of a Tumor Marker: An Example with Cathepsin D in Breast Cancer
N. Bossard, F. Descotes, A.G. Bremond, Y. Bobin, P. De Saint Hilaire, F. Golfier, A. Awada, P.M. Mathevet, L. Berrerd, Y. Barbier, J. Estève
Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer
Anne-Renee Hartman, Amy Grekowicz, Bert L. Lum, Robert W. Carlson, Christine Schurman, Branimir I. Sikic, Richard Shapiro, Frank E. Stockdale